Ranbaxy

SC holds former Ranbaxy promoters Malvinder, Shivinder Singh guilty of contempt of court

  The apex curt had earlier asked the Singh brothers to give it a plan as to how they would honour the arbitral award of Rs 3,500 crore granted by a Singapore tribunal against them and in favour of Japanese drug manufacturer Daiichi Sankyo.

Former Ranbaxy promoters Shivinder and Malvinder Singh sent to custody

  A Delhi Court on Thursday sent former Ranbaxy promoter Singh brothers and three others to judicial custody till October 31 in the Religare fraud case. Malvinder and Shivender Singh along with Sunil Godhwani, Anil Saxena and Kavi Arora were produced before link judge Nishant Garg as Chief Metropolitan Magistrate Deepak Sehrawat was on leave.

Delhi court grants 4-day custodial interrogation of Singh brothers

A Delhi court Friday granted the police 4-day custody of former Fortis Healthcare promoters, Malvinder Singh, his brother Shivinder and three others, arrested for allegedly misappropriating funds of Religare Finvest Ltd (RFL), causing it losses of Rs 2,397 crore.

Ranbaxy former promoter Shivinder Singh arrested in fraud case

Former Ranbaxy promoter Shivinder Singh has been arrested by the Delhi Police in a cheating/fraud case of Rs 740 crores. Reports suggest Religare's ex-CMD Sunil Godhwani along with two others have also been arrested. The said arrests have been made by the Economic Offences Wing. Reportedly, a lookout notice has been issued against the other brother Malvinder Singh.

SC dissatisfied over replies filed by ex-Ranbaxy promoters, will hear contempt petition on April 11

The Supreme Court on Friday expressed dissatisfaction over the replies filed by former Ranbaxy promoters Malvinder Singh and Shivinder Singh in response to its March 14 direction asking them to submit a concrete plan for paying Rs 4,000 crore to Daiichi Sankyo as directed by a Singapore tribunal.

SC asks ex-Ranbaxy promoters to apprise how they'll comply with Rs 3500 cr arbitral award

Ranbaxy row: HC bars Singh bothers from stake sale without court nod

The court’s directions came on an interim application by Japanese conglomerate Daiichi Sankyo, which had bought a majority stake in Ranbaxy in 2008

Big blow to Ranbaxy brothers, court asks them to pay Rs 2,562 crore fine to Daiichi

New Delhi: Former owners of Ranbaxy Laboratories Malvinder Singh and Shivinder Mohan Singh, have been asked by a Singapore court to pay damages worth $400 million (over Rs 2,500 crore) to Japan's Daiichi Sankyo Co.

Shivinder Mohan Singh of Fortis renounces business to join spiritual sect

New Delhi: The co-founder of Fortis Healthcare, Shivinder Mohan Singh, has sprung a surprise by renouncing the corporate world and joining a spiritual organisation. The 40-year-old responded to a higher calling and will soon be

US lawsuit puts generic drug imports from India under scanner

Washington: A US class action lawsuit accusing India's Ranbaxy of large-scale deception on its generic drug applications puts a question mark on drug imports from India, the largest supplier of generic drugs to the US.The

#Salmanverdict: Who will suffer the most if he gets convicted?

May 6th, the judgment day of actor Salman Khan's hit-and-run case is not only critical for him but for several others who are associated with the megastar. As per a media reports, around 2000 crore

Sun Pharma, Ranbaxy merger finalized, a year after announcement

New Delhi: Sun Pharmaceutical Industries today said that its merger with Ranbaxy has been 'consummated' following receipt of requisite approvals, almost a year it announced the $4 billion deal.In a filing to the BSE, the

Sun gets US trade regulator nod for Ranbaxy merger

New Delhi: Drug major Sun Pharma is now a step closer to becoming the world's fifth-largest generic drug company, as the US Federal Trade Commission (USFTC) has given a conditional nod for the proposed $4-billion

US regulator imposes conditions on Sun's Ranbaxy acquisition

Washington: An American federal trade regulator today imposed conditions on Sun Pharmaceuticals' acquisition of Ranbaxy on the grounds that the USD 4 billion proposed deal would likely be anti-competitive.The Federal Trade Commission (FTC) said pharmaceutical

US FDA forfeits Ranbaxy's exclusivity for stomach drugs

New Delhi: Drug major Ranbaxy said that the US health regulator has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets."We have now received a

Ranbaxy posts Rs 477.75-cr net profit in Q2

New Delhi: Drug maker Ranbaxy Laboratories has posted a net profit of Rs 477.75 crore for the quarter-ended September 30 due to strong topline, lower expenses and operational performance despite higher finance and tax cost,

Ranbaxy gets FDA nod to sell generic Diovan tablets in US

New Delhi: Drug major Ranbaxy Laboratories has received the U.S. health regulator's approval to market a generic version of Novartis' Diovan tablets, used for treating high blood pressure and heart failure, in the U.S. with

Andhra HC lifts stay on merger between Ranbaxy and Sun Pharma

Hyderabad: The Andhra Pradesh High Court today vacated a status quo order it had issued earlier on Sun Pharma-Ranbaxy merger process, paving the way for the pharma giants becoming a single entity.While vacating the status

SC asks Andhra HC to decide on Ranbaxy-Sun Pharma merger

New Delhi: The Supreme Court today asked the Andhra Pradesh High Court, which had passed an interim order staying the $4 billion merger of Ranbaxy with Sun Pharma, to decide the issue within two days.Hearing

Ranbaxy's journey as a company to end after merger with Sun

New Delhi: Ranbaxy  Laboratories will cease to exist as a company after completion of the $ 4 billion merger with Sun Pharmaceuticals, although its brands will be kept alive in over 100 markets. “The Ranbaxy entity